|
|
Blood, 1 October 2007, Vol. 110, No. 7, pp. 2316-2323.
Prepublished online as a Blood First Edition Paper on June 20, 2007; DOI 10.1182/blood-2007-02-074641.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Andrea Gallamini1,
Francesco Zaja2,
Caterina Patti3,
Atto Billio4,
Maria Rosaria Specchia5,
Alessandra Tucci6,
Alessandro Levis7,
Annunziata Manna8,
Vicenzo Secondo9,
Luigi Rigacci10,
Antonello Pinto11,
Emilio Iannitto12,
Valerio Zoli13,
Pierfederico Torchio14,
Stefano Pileri15, and
Corrado Tarella16
1 Hematology Department, Ospedale Santa Croce, Cuneo;
2 Hematology Department, Università di Udine, Udine;
3 Hematology Department, Ospedale Cervello, Palermo, Sicily;
4 Hematology Department, Ospedale Regionale Generale, Bolzano;
5 Hematology Department, Ospedale Santa Giuseppe Moscati, Taranto;
6 Hematology Department, Ospedale Spedali Civili, Brescia;
7 Hematology Department, Ospedale Santa Antonio e Biagio, Alessandria;
8 Onco-Hematology Department, Ospedale Azienda Sanitaria Locale 5, La Spezia;
9 Internal Medicine Department, Ospedale Galliera, Genova;
10 Hematology Department, Università di Firenze, Firenze;
11 Onco-Hematology Department, Ospedale Pascale, Napoli;
12 Hematology Department, Università di Palermo, Palermo, Sicily;
13 Hematology Department, Ospedale Santa Camillo Forlanini, Roma;
14 Medical Statistics Department, Università di Torino, Torino;
15 Hemolymphopathology Department, Università di Bologna, Bologna;
16 Hematology Department, Università di Torino, Torino, Italy
To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day –1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follow-up of 16 months (range, 5-42 months), 14 patients were alive, 9 had died from progressive disease, and 1 had died from pneumonia at day +198 while in CR. So far, 13 are disease-free, with an overall median duration of response of 11 months. The most frequent side effects were grade 4 neutropenia and cytomegalovirus (CMV) reactivation. Major infections were Jacob-Creutzfeldt (J-C) virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis, and pneumonia. This study shows that CHOP-C: (1) is a feasible chemoimmunotherapy regimen; (2) is effective in PTCL with a high rate of CR achievement; and (3) is associated with mostly manageable infectious complications. This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID no. 141202.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. J. Kim, K. Kim, B. S. Kim, C. Suh, J. Huh, Y. H. Ko, and W. S. Kim
Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study
Ann. Onc.,
February 1, 2009;
20(2):
390 - 392.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Reimer, T. Rudiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. K. Muller-Hermelink, and M. Wilhelm
Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study
J. Clin. Oncol.,
January 1, 2009;
27(1):
106 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini, et al.
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
J. Clin. Pathol.,
November 1, 2008;
61(11):
1160 - 1167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. C. Kluin-Nelemans, J. L. Coenen, J. E. Boers, G. W. van Imhoff, and S. Rosati
EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
Blood,
August 15, 2008;
112(4):
1039 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Jaeger, F. Bauer, R. Brezinschek, C. Beham-Schmid, C. Mannhalter, and P. Neumeister
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine
Ann. Onc.,
May 1, 2008;
19(5):
1025 - 1026.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Chen, R. H. Advani, and K. G. Robinson
Beyond the Guidelines in the Treatment of Peripheral T-Cell Lymphoma: New Drug Development
J Natl Compr Canc Netw,
April 1, 2008;
6(4):
428 - 435.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Koo and L. R. Baden
Infectious Complications Associated With Immunomodulating Monoclonal Antibodies Used in the Treatment of Hematologic Malignancy
J Natl Compr Canc Netw,
February 1, 2008;
6(2):
202 - 213.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. M. Horwitz
Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas
Hematology,
January 1, 2008;
2008(1):
289 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
